Company intelligence / Profile preview

Royal Biologics

Hackensack, New Jersey, United Statesroyalbiologics.com ↗

Ownership: Private
Employees: ~27
Development stage: Other

Overview

Royal Biologics has launched several commercial products including the BIO‑REIGN™ line of bone graft substitutes. The company’s portfolio includes advanced cellular technologies and regenerative medicine platforms focused on musculoskeletal healing and wound care. Clinical results are not detailed publicly but the company emphasizes innovation in autologous cell-based therapies and proprietary biomaterials that support cell proliferation, vascularization, and new tissue growth.

Therapeutic areas: OtherDermatologyRheumatology
Modalities: Cell therapyBiologicDevicePolymer-based therapy
Industry: Therapeutic Medical Devices

Partnerships

Licensing agreement with Molecular Matrix for Osteo-P® BGS technology underlying BIO‑REIGN™.

Beyond the preview

Go deeper on Royal Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Royal Biologics.